Lucid and collaborators will present data on
three studies on EsoGuard® esophageal precancer testing and one on
a new genetic classifier of esophageal neoplasia
NEW
YORK, March 20, 2024 /PRNewswire/ -- Lucid
Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a
commercial-stage, cancer prevention medical diagnostics company,
and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ)
( "PAVmed"), today announced that four abstracts related to its
groundbreaking technologies, including its EsoGuard®
Esophageal DNA Test, have been accepted for presentation by it and
its collaborators at this year's Digestive Disease Week (DDW)
Annual Meeting 2024—the world's premier meeting for digestive
disease professionals.
"We are excited that our technologies will be prominently
featured in multiple presentations at this year's DDW conference,"
said Suman Verma, M.D., Ph.D., Lucid
Senior Vice President, and Chief Scientific Officer. "The data from
these studies build on the strong, expanding clinical evidence base
for EsoGuard testing to detect esophageal precancer and introduce a
new genetic classifier with the potential to serve as a marker of
progression from early esophageal precancer to late precancer or
cancer."
Dr. Verma will present two abstracts entitled:
- Detection of Barrett's Esophagus using Nonendoscopic
Methylated Vimentin and CCNA1 Biomarker Testing in a Screening
Population Based on ACG Guidelines; and
- Genetic Classifier to Differentiate Late Stage Barrett's
Esophagus (HGD) and Esophageal Adenocarcinoma (EAC) from
Early-Stage Disease (NDBE & LGD).
Collaborators from the Case Western Reserve
University School of Medicine will present two additional
abstracts entitled:
- Nonendoscopic Detection of Barrett's Esophagus in Patients
without GERD Symptoms; and
- Assessment of Patient Attitudes Towards Non-Endoscopic
Barrett's Esophagus Screening.
DDW 2024 will be held at the Walter E. Washington Convention
Center in Washington, D.C.,
May 18 to 24, 2024. Details on the
time and location of the presentations will be provided prior to
the conference.
About Lucid Diagnostics
Lucid Diagnostics Inc. is a commercial-stage medical diagnostics
company focused on cancer prevention, and subsidiary of PAVmed Inc.
(Nasdaq: PAVM). Lucid is focused on the millions of patients with
gastroesophageal reflux disease (GERD), also known as chronic
heartburn, who are at risk of developing esophageal precancer and
cancer. Lucid's EsoGuard® Esophageal DNA Test, performed
on samples collected in a brief, noninvasive office procedure with
its EsoCheck Esophageal Cell Collection Device, is the first and
only commercially available diagnostic test capable of serving as a
widespread screening tool for at-risk patients to mitigate the
risks of cancer and cancer deaths through early detection of
esophageal precancer.
For more information, please visit www.luciddx.com and for more
information about its parent company PAVmed, please visit
www.pavmed.com.
Forward-Looking Statements
This press release includes forward-looking statements that
involve risk and uncertainties. Forward-looking statements are any
statements that are not historical facts. Such forward-looking
statements, which are based upon the current beliefs and
expectations of Lucid's management, are subject to risks and
uncertainties, which could cause actual results to differ from the
forward-looking statements. Risks and uncertainties that may cause
such differences include, among other things, volatility in the
price of Lucid's common stock; general economic and market
conditions; the uncertainties inherent in research and development,
including the cost and time required to advance Lucid's products to
regulatory submission; whether regulatory authorities will be
satisfied with the design of and results from Lucid's clinical and
preclinical studies; whether and when Lucid's products are cleared
by regulatory authorities; market acceptance of Lucid's products
once cleared and commercialized; Lucid's ability to raise
additional funding as needed; and other competitive developments.
In addition, Lucid continues to monitor the COVID-19 pandemic and
the pandemic's impact on Lucid's businesses. These factors are
difficult or impossible to predict accurately and many of them are
beyond Lucid's control. In addition, new risks and uncertainties
may arise from time to time and are difficult to predict. For a
further list and description of these and other important risks and
uncertainties that may affect Lucid's future operations, see Part
I, Item 1A, "Risk Factors," in Lucid's most recent Annual Report on
Form 10-K filed with the Securities and Exchange Commission, as the
same may be updated in Part II, Item 1A, "Risk Factors" in any
Quarterly Report on Form 10-Q filed by Lucid Diagnostics after its
most recent Annual Report. Lucid disclaims any intention or
obligation to publicly update or revise any forward-looking
statement to reflect any change in its expectations or in events,
conditions, or circumstances on which those expectations may be
based, or that may affect the likelihood that actual results will
differ from those contained in the forward-looking statements.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/lucid-diagnostics-announces-multiple-presentations-at-the-upcoming-digestive-disease-week-ddw-2024-conference-302094543.html
SOURCE Lucid Diagnostics